Although AstraZeneca PLC wasn’t one of the first PD-1/LI sponsors to make it to market, new Phase III data may position the company’s Imfinzi (durvalumab) to be an early entrant for neoadjuvant treatment of non-small cell lung cancer (NSCLC), a space where Bristol Myers Squibb Company’s PD-1 inhibitor Opdivo (nivolumab) had the distinction of winning US Food and Drug Administration approval earlier this year and where other PD-1/L1 players are hoping to compete as well.
The British drug maker is busy at work making Imfinzi a player in earlier lines of treatment, such as neoadjuvant as well as adjuvant treatment of solid tumors, which is still a relatively untapped field for the checkpoint inhibitors. AstraZeneca made a point of not chasing the leaders into the initial lung cancer market and carving out its own niche indication for unresectable Stage III NSCLC
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?